共 49 条
Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial
被引:168
作者:
Alberu, Josefina
[1
]
Pascoe, Michael D.
[2
]
Campistol, Josep M.
[3
]
Schena, Francesco P.
[4
]
del Carmen Rial, Maria
[5
]
Polinsky, Martin
[6
]
Neylan, John F.
[6
]
Korth-Bradley, Joan
[6
]
Goldberg-Alberts, Robert
[6
]
Maller, Eric S.
[6
]
机构:
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Trasplantes, Mexico City 14080, DF, Mexico
[2] Univ Cape Town, Div Nephrol, Groote Schuur Hosp, ZA-7925 Cape Town, South Africa
[3] Hosp Clin Barcelona, Inst Clin Nefrol & Urol, Unidad Transplant Renal, Barcelona, Spain
[4] Univ Bari, Renal Dialysis & Transplant Unit, Dept Emergency & Organ Transplant, Bari, Italy
[5] Inst Nefrol, Dept Clin Res, Buenos Aires, DF, Argentina
[6] Wyeth Res, Collegeville, PA USA
关键词:
Sirolimus;
Calcineurin inhibitor;
Malignancy;
Immunosuppression;
Kidney transplantation;
EARLY CYCLOSPORINE WITHDRAWAL;
DE-NOVO MALIGNANCIES;
KIDNEY-TRANSPLANT RECIPIENTS;
MAMMALIAN TARGET;
IMMUNOSUPPRESSIVE THERAPY;
MYCOPHENOLATE-MOFETIL;
RAPAMYCIN INHIBITORS;
REDUCED INCIDENCE;
CYCLOPHILIN-A;
RISK;
D O I:
10.1097/TP.0b013e3182247ae2
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
071005 [微生物学];
100108 [医学免疫学];
摘要:
Background. Long-term immunosuppression imposes increased malignancy risk in renal allograft recipients, significantly contributing to overall morbidity and mortality. This study examined malignancy rates in renal allograft recipients at 2 years after conversion to a sirolimus (SRL)-based, calcineurin inhibitor (CNI)-free regimen. Methods. This open-label, randomized, multicenter study (the CONVERT Trial) randomly assigned 830 patients to SRL conversion (n = 555) or CNI continuation (n = 275). Patients with history of posttransplant lymphoproliferative disease or known/suspected malignancy within 5 years before screening were excluded. As part of standard safety measurements, subjects were monitored for any malignancy occurrence; both skin and nonskin malignancies were reported, even if the patient discontinued from the therapy. Malignancy rates were analyzed based on exposure time to study drugs (i.e., number of events per 100 person-years of follow-up). Results. At 2 years postconversion, the total number of malignancies per 100 person-years of exposure was significantly lower among SRL conversion patients compared with CNI continuation (2.1 vs. 6.0, P<0.001). Patients undergoing SRL-based, CNI-free therapy had significantly lower rates of the subset of nonmelanoma skin carcinomas through 2 years postconversion (1.2 vs. 4.3, P<0.001). This difference persisted after excluding patients with a history of malignancy before randomization. The rate of all other malignancies was not significantly different between treatment groups (P = 0.058). Conclusion. In renal allograft recipients, SRL-based immunosuppression was associated with a lower rate of malignancy at 2 years postconversion compared with continuation of CNI-based immunosuppression. This reduction was driven by a significant reduction in nonmelanoma skin carcinoma rates; the rate of all other malignancies was numerically lower but did not achieve statistical significance.
引用
收藏
页码:303 / 310
页数:8
相关论文

